Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Contribution of Host Immune Responses Against Influenza D Virus Infection Toward Secondary Bacterial Infection in a Mouse Model.

Skelton RM, Shepardson KM, Hatton A, Wilson PT, Sreenivasan C, Yu J, Wang D, Huber VC, Rynda-Apple A.

Viruses. 2019 Oct 29;11(11). pii: E994. doi: 10.3390/v11110994.

2.

Development of a multiplex real-time RT-PCR assay for simultaneous detection and differentiation of influenza A, B, C, and D viruses.

Zhang H, Wang Y, Porter E, Lu N, Li Y, Yuan F, Lohman M, Noll L, Zheng W, Stoy C, Lang Y, Huber VC, Ma W, Peddireddi L, Fang Y, Shi J, Anderson G, Liu X, Bai J.

Diagn Microbiol Infect Dis. 2019 Sep;95(1):59-66. doi: 10.1016/j.diagmicrobio.2019.04.011. Epub 2019 Apr 29.

PMID:
31130238
3.

A Novel Role for PDZ-Binding Motif of Influenza A Virus Nonstructural Protein 1 in Regulation of Host Susceptibility to Postinfluenza Bacterial Superinfections.

Shepardson K, Larson K, Cho H, Johns LL, Malkoc Z, Stanek K, Wellhman J, Zaiser S, Daggs-Olson J, Moodie T, Klonoski JM, Huber VC, Rynda-Apple A.

Viral Immunol. 2019 Apr;32(3):131-143. doi: 10.1089/vim.2018.0118. Epub 2019 Mar 1.

PMID:
30822217
4.

The Streptococcus pyogenes fibronectin/tenascin-binding protein PrtF.2 contributes to virulence in an influenza superinfection.

Herrera AL, Faal H, Moss D, Addengast L, Fanta L, Eyster K, Huber VC, Chaussee MS.

Sci Rep. 2018 Aug 14;8(1):12126. doi: 10.1038/s41598-018-29714-x.

5.

Contributions of Influenza Virus Hemagglutinin and Host Immune Responses Toward the Severity of Influenza Virus: Streptococcus pyogenes Superinfections.

Klonoski JM, Watson T, Bickett TE, Svendsen JM, Gau TJ, Britt A, Nelson JT, Schlenker EH, Chaussee MS, Rynda-Apple A, Huber VC.

Viral Immunol. 2018 Jul/Aug;31(6):457-469. doi: 10.1089/vim.2017.0193. Epub 2018 Jun 5.

6.

The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Smith AM, Huber VC.

Viral Immunol. 2018 Mar;31(2):159-173. doi: 10.1089/vim.2017.0138. Epub 2017 Nov 17. Review.

7.

Binding host proteins to the M protein contributes to the mortality associated with influenza-Streptococcus pyogenes superinfections.

Herrera AL, Suso K, Allison S, Simon A, Schlenker E, Huber VC, Chaussee MS.

Microbiology. 2017 Oct;163(10):1445-1456. doi: 10.1099/mic.0.000532.

8.

So You Want To Be A Reviewer.

Vogt HB, Huber VC, Hansen KA.

S D Med. 2017 Mar;70(3):127-133.

PMID:
28813775
9.

Establishment of memory CD8+ T cells with live attenuated influenza virus across different vaccination doses.

Wang Z, Kedzierski L, Nuessing S, Chua BYL, QuiƱones-Parra SM, Huber VC, Jackson DC, Thomas PG, Kedzierska K.

J Gen Virol. 2016 Dec;97(12):3205-3214. doi: 10.1099/jgv.0.000651. Epub 2016 Nov 2.

PMID:
27902386
11.

Differential Type I Interferon Signaling Is a Master Regulator of Susceptibility to Postinfluenza Bacterial Superinfection.

Shepardson KM, Larson K, Morton RV, Prigge JR, Schmidt EE, Huber VC, Rynda-Apple A.

mBio. 2016 May 3;7(3). pii: e00506-16. doi: 10.1128/mBio.00506-16.

13.

The Association between Invasive Group A Streptococcal Diseases and Viral Respiratory Tract Infections.

Herrera AL, Huber VC, Chaussee MS.

Front Microbiol. 2016 Mar 21;7:342. doi: 10.3389/fmicb.2016.00342. eCollection 2016. Review.

14.

Construction and Immunogenicity Evaluation of Recombinant Influenza A Viruses Containing Chimeric Hemagglutinin Genes Derived from Genetically Divergent Influenza A H1N1 Subtype Viruses.

McCormick K, Jiang Z, Zhu L, Lawson SR, Langenhorst R, Ransburgh R, Brunick C, Tracy MC, Hurtig HR, Mabee LM, Mingo M, Li Y, Webby RJ, Huber VC, Fang Y.

PLoS One. 2015 Jun 10;10(6):e0127649. doi: 10.1371/journal.pone.0127649. eCollection 2015.

15.

Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.

Klonoski JM, Hurtig HR, Juber BA, Schuneman MJ, Bickett TE, Svendsen JM, Burum B, Penfound TA, Sereda G, Dale JB, Chaussee MS, Huber VC.

Vaccine. 2014 Sep 8;32(40):5241-9. doi: 10.1016/j.vaccine.2014.06.093. Epub 2014 Jul 29.

16.

Enhanced response to pulmonary Streptococcus pneumoniae infection is associated with primary ciliary dyskinesia in mice lacking Pcdp1 and Spef2.

McKenzie CW, Klonoski JM, Maier T, Trujillo G, Vitiello PF, Huber VC, Lee L.

Cilia. 2013 Dec 20;2(1):18. doi: 10.1186/2046-2530-2-18.

17.

Influenza vaccines: from whole virus preparations to recombinant protein technology.

Huber VC.

Expert Rev Vaccines. 2014 Jan;13(1):31-42. doi: 10.1586/14760584.2014.852476. Review.

PMID:
24192014
18.

Construction and immunogenicity evaluation of an epitope-based antigen against swine influenza A virus using Escherichia coli heat-labile toxin B subunit as a carrier-adjuvant.

Sun Z, Lawson S, Langenhorst R, McCormick KL, Brunick C, Opriessnig T, Baker R, Yoon KJ, Zhang W, Huber VC, Fang Y.

Vet Microbiol. 2013 Jun 28;164(3-4):229-38. doi: 10.1016/j.vetmic.2013.02.010. Epub 2013 Feb 26.

PMID:
23497910
19.

Can surveillance of the influenza virus PB1-F2 gene be used to predict the severity of secondary bacterial infections?

Huber VC.

Virulence. 2012 Oct 1;3(6):523-4. doi: 10.4161/viru.21811. Epub 2012 Oct 1. No abstract available.

20.

Characterization of a porcine intestinal epithelial cell line for influenza virus production.

Sun Z, Huber VC, McCormick K, Kaushik RS, Boon AC, Zhu L, Hause B, Webby RJ, Fang Y.

J Gen Virol. 2012 Sep;93(Pt 9):2008-16. doi: 10.1099/vir.0.044388-0. Epub 2012 Jun 27.

21.

Naturally occurring swine influenza A virus PB1-F2 phenotypes that contribute to superinfection with Gram-positive respiratory pathogens.

Weeks-Gorospe JN, Hurtig HR, Iverson AR, Schuneman MJ, Webby RJ, McCullers JA, Huber VC.

J Virol. 2012 Sep;86(17):9035-43. doi: 10.1128/JVI.00369-12. Epub 2012 Jun 6.

22.

Correlates of vaccine protection from influenza and its complications.

McCullers JA, Huber VC.

Hum Vaccin Immunother. 2012 Jan;8(1):34-44. doi: 10.4161/hv.8.1.18214. Epub 2012 Jan 1. Review.

PMID:
22252001
23.

Contribution of murine innate serum inhibitors toward interference within influenza virus immune assays.

Cwach KT, Sandbulte HR, Klonoski JM, Huber VC.

Influenza Other Respir Viruses. 2012 Mar;6(2):127-35. doi: 10.1111/j.1750-2659.2011.00283.x. Epub 2011 Aug 29.

24.

Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer.

Halasa N, Englund JA, Nachman S, Weinberg GA, Huber VC, Allison K, Dubovsky F, Yi T, McCullers JA, Flynn PM.

Vaccine. 2011 May 31;29(24):4110-5. doi: 10.1016/j.vaccine.2011.03.097. Epub 2011 Apr 13.

PMID:
21496468
25.

Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections.

Chaussee MS, Sandbulte HR, Schuneman MJ, Depaula FP, Addengast LA, Schlenker EH, Huber VC.

Vaccine. 2011 May 12;29(21):3773-81. doi: 10.1016/j.vaccine.2011.03.031. Epub 2011 Apr 8.

26.

Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications.

Huber VC, Peltola V, Iverson AR, McCullers JA.

J Virol. 2010 Apr;84(8):4105-8. doi: 10.1128/JVI.02621-09. Epub 2010 Feb 3.

27.

A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.

Huber VC, Thomas PG, McCullers JA.

Vaccine. 2009 Feb 18;27(8):1192-200. doi: 10.1016/j.vaccine.2008.12.023. Epub 2009 Jan 7.

28.

Vaccines against pandemic influenza: what can be done before the next pandemic?

Huber VC, McCullers JA.

Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S113-7. doi: 10.1097/INF.0b013e318168b749.

PMID:
18820570
29.

Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus.

Huber VC, Kleimeyer LH, McCullers JA.

Vaccine. 2008 Oct 3;26(42):5381-8. doi: 10.1016/j.vaccine.2008.07.086. Epub 2008 Aug 15.

30.

FluBlok, a recombinant influenza vaccine.

Huber VC, McCullers JA.

Curr Opin Mol Ther. 2008 Feb;10(1):75-85.

PMID:
18228185
31.

Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza.

Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH, McCullers JA.

Clin Vaccine Immunol. 2006 Sep;13(9):981-90.

32.

Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets.

Huber VC, McCullers JA.

J Infect Dis. 2006 Mar 1;193(5):677-84. Epub 2006 Jan 27.

PMID:
16453263
33.
34.
35.

The dietary supplement ephedrine induces beta-adrenergic mediated exacerbation of systemic lupus erythematosus in NZM391 mice.

Hudson CA, Mondal TK, Cao L, Kasten-Jolly J, Huber VC, Lawrence DA.

Lupus. 2005;14(4):293-307.

PMID:
15864916
36.

Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity.

Huber VC, Arulanandam BP, Arnaboldi PM, Elmore MK, Sheehan CE, Kallakury BV, Metzger DW.

Int Immunopharmacol. 2003 Jun;3(6):801-9.

PMID:
12781697
37.

Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections.

Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW.

J Immunol. 2001 Jun 15;166(12):7381-8.

Supplemental Content

Loading ...
Support Center